Intermedics Orthopedics' knee gets favourable panel review
This article was originally published in Clinica
Intermedics Orthopedics' (US) Natural Knee prosthesis received a unanimous recommendation for conditional US marketing approval by the FDA's Orthopaedic and Rehabilitation Devices Advisory Panel on June 12th. The recommendation was for cementless use of the implant in skeletally mature individuals. The panel recommended that Intermedics be required to perform additional ex vivo studies to measure the ability of the prosthesis to withstand shear forces and to perform post- marketing follow-up studies in patients.
You may also be interested in...
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.